Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 1999

View Archived Issues

Selected purine analogues tested as angiogenesis inhibitors

Vivus terminates agreement with Bio-Medic Institute

HMR grants Fujisawa option to license malononitrilamide compounds

Major clinical study demonstrates efficacy and safety of Aviron's intranasal flu vaccine

Epimmune receives notice of allowance for patent covering vaccine technology

Zadaxin triple therapy shows promising results in preclinical model of colorectal cancer

Avigen licenses AAV-factor IX technology from the Children's Hospital of Philadelphia

York Medical gives update on development of anti-EGF receptor MAb for cancer Rx/Dx

Oral hepatitis B plant vaccine begins clinical trials in U.S.

ABT-431: the first D1 agonist with demonstrated antiparkinsonian activity in patients

U.S. patent issues for Celgene's ADHD treatment

NeXstar begins enrolling patients in U.S. phase I trial of NX-211

Onconase/interferon combination exerts synergistic antitumor activity in vitro

Broad-spectrum antivirals with heterocyclic structure developed at BioChem Pharma

Agents for AIDS extracted from plant source

Tetrionics will supply 2ME2 for EntreMed's preclinical testing program

Insulin secretion enhancers under study at Lilly for use in conditions of impaired glucose disposal

Bristol-Myers Squibb patents new series of CDK inhibitors

Novel pyridazines from Kowa inhibit cytokine production

Antitumor spectrum of Sch-66336 determined in human tumor cloning assay

New integrin receptor antagonists in the Merck pipeline

KRP-197: new bladder-selective antimuscarinic agent in clinical trials for bladder dysfunction

Xenova sells MetaXen to Exelixis

Licensing opportunity from NIH: method of preventing or reducing ischemic injury of the heart

Planned Rhone-Poulenc/Hoechst merger moves forward on schedule

Potent, orally active AVP receptor antagonist increases urine output in rats

Satellite symposium on antiarrhythmics underlines particular promise of dronedarone

TT-232, a new somatostatin analogue, effective against neurogenic and non-neurogenic inflammation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...